Gordan G S, Halden A, Walter R M
Calif Med. 1970 Sep;113(3):1-10.
Twenty-two women with far advanced, hormone-refractory breast cancer were treated with 7beta,17alpha dimethyltestosterone (calusterone), 150 to 300 mg per day by mouth, to test its antitumor efficacy. Using the strict criteria of the Cooperative Breast Cancer Group, 14 of the women (64 percent) obtained objective regressions. Regressions lasted for from 3 to 20 months, averaging 7 months. Undesirable actions are those of a 17alpha-alkylated, weak androgen with inconstant bromsulphalein retention, but without elevation of serum bilirubin levels or of hepatic enzymes.This compound has potent antitumor efficacy in women with advanced breast cancer, is better tolerated than most chemotherapeutic or steroidal antitumor agents, and will probably assume an important position in the care of these patients.
22名患有晚期激素难治性乳腺癌的女性接受了7β,17α-二甲基睾酮（卡鲁睾酮）治疗，口服剂量为每日150至300毫克，以测试其抗肿瘤疗效。根据乳腺癌协作组的严格标准，其中14名女性（64%）获得了客观缓解。缓解持续3至20个月，平均7个月。不良反应是17α-烷基化弱雄激素的不良反应，溴磺酞钠潴留情况不一，但血清胆红素水平和肝酶无升高。这种化合物对晚期乳腺癌女性具有强效抗肿瘤疗效，耐受性优于大多数化疗或甾体类抗肿瘤药物，可能会在这些患者的治疗中占据重要地位。
